Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
12/06/201506:00Business WireAcceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology AssociationNASDAQ:XLRNAcceleron Pharma Inc
10/06/201516:13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
09/06/201515:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
09/06/201506:30Business WireAcceleron Pharma to Host Conference Call & Webcast to Review New Luspatercept Data Presented at the 20th Congress of the Euro...NASDAQ:XLRNAcceleron Pharma Inc
09/06/201506:14The Motley FoolStocks To Watch in Orphan DrugsNASDAQ:XLRNAcceleron Pharma Inc
07/06/201507:11The Motley FoolThese 3 Ultra-Rare Diseases Are Utterly TerrifyingNASDAQ:XLRNAcceleron Pharma Inc
03/06/201515:30Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:XLRNAcceleron Pharma Inc
27/05/201506:30Business WireAcceleron Pharma to Present at Upcoming Investor Conferences in JuneNASDAQ:XLRNAcceleron Pharma Inc
26/05/201516:15Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:XLRNAcceleron Pharma Inc
21/05/201515:05Business WireAcceleron to Present Luspatercept Clinical Trials at the 20th Congress of the European Hematology AssociationNASDAQ:XLRNAcceleron Pharma Inc
18/05/201506:30Business WireFDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-ThalassemiaNASDAQ:XLRNAcceleron Pharma Inc
13/05/201516:15Business WireAcceleron to Present Dalantercept Clinical Data at the 2015 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:XLRNAcceleron Pharma Inc
07/05/201506:29Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XLRNAcceleron Pharma Inc
07/05/201506:00Business WireAcceleron Pharma Reports First Quarter 2015 Financial and Operational ResultsNASDAQ:XLRNAcceleron Pharma Inc
06/05/201508:10Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:XLRNAcceleron Pharma Inc
02/05/201509:30Business WireLuspatercept Data Presented at the 13th International Symposium on Myelodysplastic SyndromesNASDAQ:XLRNAcceleron Pharma Inc
01/05/201514:04Analyst Ratings NetworkAcceleron Pharma's "Hold" Rating Reiterated at Zacks (XLRN)NASDAQ:XLRNAcceleron Pharma Inc
30/04/201506:35Business WireCelgene and Acceleron Select Luspatercept to Advance to Phase 3 in Myelodysplastic SyndromesNASDAQ:XLRNAcceleron Pharma Inc
28/04/201506:30Business WireAcceleron Pharma to Host First Quarter 2015 Financial Results Conference Call and Webcast on May 7, 2015NASDAQ:XLRNAcceleron Pharma Inc
23/04/201506:30Business WireAcceleron Pharma to Present at Upcoming Investor Conferences in MayNASDAQ:XLRNAcceleron Pharma Inc
21/04/201509:51The Motley Fool3 Bursting Biotech Stocks -- 1 To BuyNASDAQ:XLRNAcceleron Pharma Inc
17/04/201515:43Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XLRNAcceleron Pharma Inc
17/04/201515:42Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XLRNAcceleron Pharma Inc
10/04/201515:19Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:XLRNAcceleron Pharma Inc
07/04/201506:00Business WireAcceleron Announces Oral Presentations of Luspatercept & Sotatercept Data at the 13th International Symposium on Myelodysplas...NASDAQ:XLRNAcceleron Pharma Inc
06/04/201506:00Business WireAcceleron Pharma Appoints Dr. Francois Nader as Chairman of its Board of DirectorsNASDAQ:XLRNAcceleron Pharma Inc
06/03/201507:00Business WireAcceleron Pharma Announces Executive Appointments and PromotionsNASDAQ:XLRNAcceleron Pharma Inc
02/03/201510:56Edgar (US Regulatory)Annual Report (10-k)NASDAQ:XLRNAcceleron Pharma Inc
02/03/201506:00Business WireAcceleron Pharma Reports Fourth Quarter and Year Ended 2014 Financial and Operational ResultsNASDAQ:XLRNAcceleron Pharma Inc
28/02/201509:00Business WireAcceleron Presents Encouraging Response Rates & Progression-Free Survival Data in Patients with Advanced Renal Cell Carcinoma...NASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN

Su Consulta Reciente

Delayed Upgrade Clock